drugset

drugset / Trial / NCT00690170

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170 ↗

Phase 1 Completed 30 enrolled Yale University

RandomizedCrossoverTriple-blindBasic science

Summary

This study examines the interactive effects of ketamine and nicotine.

Timeline

Start: 2002-12
Primary completion: 2009-06
Completion: 2009-09

Publications

D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry. 2012 Nov 1;72(9):785-94. doi: 10.1016/j.biopsych.2012.05.009. Epub 2012 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ketamine	Small molecule	0.29 mg/kg	Intravenous
Comparator	Nicotine	Unknown	31.02 ug/kg	Intravenous

Indications

No indication recorded.